View Clinical Trial (Medical Research Study)

AB103 Peptide Antagonist in Healthy Volunteers - NCT01166984-21201(Clinical Trial 702950)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Baltimore
State:  
MD
Zip Code: 21201
Conditions: Healthy Volunteers
Purpose: The primary objective of this study is to establish the safety profile and maximum tolerated dose of AB103 given as a single intravenous infusion or by repeated (5 days) IV infusions in healthy volunteers.
Study summary: AB103 is being developed as a therapeutic to treat severe sepsis and septic shock resulting from bacterial infections. This will be a Phase 1, single center, randomized, double-blind, placebo-controlled, sequential-dose escalation study in approximately 34 healthy volunteers with an LPS challenge cohort following the dose escalation phase.
Criteria: Inclusion Criteria: - Be 18-to-40 years-of-age. - Have adequate venous access. - Have a body mass index between 20 and 29 kg/m2. - Have a history and physical examination that demonstrate no clinically significant contraindication for participating in the study, in the judgment of the admitting physician and/or the site investigator. - Have vital signs as follows: resting heart rate between 50 and 90 bpm, systolic BP below 150 mm Hg and diastolic BP below 90 mm Hg. - Have all blood chemistry, hematology, coagulation, and urinalysis analyte levels within 10% of normal laboratory limits. - If female, not be pregnant or breast-feeding, nor plan to become pregnant for the duration of the study, have a negative pregnancy test. - Agree to exercise adequate birth control from the time of the screening procedures to 14 days after the investigational agent administration (both males and females). - Have an ECG performed that demonstrates normal sinus rhythm, normal conductivity, and no clinically significant arrhythmias. Exclusion Criteria: - Be pregnant or lactating. - Have autoimmune disease or asthma. - Have been febrile within 3-days of the first infusion. - Have a history of migraine headaches, as diagnosed by a physician. - Have any acute or chronic medical illnesses or other condition that, in the opinion of the Investigator, might jeopardize the safety of the patient, or the adequate evaluation of study results. - Be taking any medications to treat a chronic medical condition. - Have participated in a research study where they received any experimental products within 30 days prior to study entry. - Have ongoing drug abuse/dependence (including alcohol) by medical history. - Have taken, within 14 days of planned dosing, any prescription or non-prescription medication (including ibuprofen, aspirin, of non-steroidal anti-inflammatory drugs) unless the Principal Investigator/Sub-Investigator, in consultation with the Medical Monitor, provides a statement justifying that the medication taken will not impact the results of this study (with rare exceptions taking prescription drugs will be grounds for exclusion). - Have donated a unit of blood within the preceding 4-week period. - Have allergy to either sulfa- or penicillin-based drugs.
Study is available at: University of Maryland School of Medicine
Baltimore, MD 21201
United States

Primary Contact:
Robin Barnes
Email: rbarnes@medicine.umaryland.edu
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.